MVK抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Raji cells, Primary antibody: P08534(MVK Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08534(MVK Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P08534(MVK Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

MVK (mevalonate kinase) antibodies are primarily associated with the study and diagnosis of mevalonate kinase deficiency (MKD), a rare autosomal recessive metabolic disorder. The MVK gene encodes the enzyme mevalonate kinase, a key player in the mevalonate pathway responsible for cholesterol synthesis and isoprenoid production. Mutations in this gene lead to reduced enzyme activity, causing accumulation of mevalonic acid and subsequent systemic inflammation.

MKD manifests as a spectrum of conditions, including hyper-IgD syndrome (HIDS) and mevalonic aciduria, characterized by recurrent febrile episodes, rash, joint pain, and gastrointestinal symptoms. MVK antibodies are utilized in research and diagnostics to detect MVK protein expression levels, aiding in confirming MKD diagnoses and understanding disease mechanisms. They also help investigate the enzyme's role in inflammatory pathways, such as inflammasome activation and IL-1β overproduction.

Clinically, detecting MVK antibodies supports genetic testing and informs therapeutic strategies, including anti-inflammatory treatments. Research using these antibodies contributes to elucidating metabolic disruptions in MKD and exploring potential targeted therapies. Their application extends to studying broader connections between mevalonate pathway dysfunction and autoinflammatory or autoimmune disorders.